Microneedle Flu Vaccine Market Analysis & Forecast: 2025-2032

Microneedle Flu Vaccine Market is estimated to be valued at USD 1,749.2 Mn in 2025 and is expected to reach USD 2,682.7 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 6.3% from 2025 to 2032.

Analysts’ Views on Global Microneedle Flu Vaccine Market:

Rising demand for microneedle flu vaccines for the treatment of influenza is expected to drive the market growth over the forecast period. For instance, in July 2020, according to a report published by ScienceDirect, an open-source journal, a new product VaxiPatch, which is a novel vaccination system comprised of subunit antigens, adjuvants, and microneedle skin delivery for the treatment of influenza was developed by Verndari, Inc., a vaccine development company.

Figure 1. Global Microneedle Flu Vaccine Market Share (%), by Product Type, 2025

To learn more about this report, Request sample copy

Global Microneedle Flu Vaccine Market- Driver

Increasing prevalence of influenza

The increasing prevalence of influenza which requires microneedle flu vaccines for its treatment is expected to drive the market growth over the forecast period. For instance, in October 2022, a report published on WebMD LLC., a full-service Internet healthcare portal, stated that an estimated 5,000 to 14,000 deaths have been attributed to influenza since October 2021.

Increasing launch of new flu prevention campaigns and initiatives by healthcare organizations

The launch of new flu prevention campaigns and initiatives by healthcare organizations is expected to drive demand for influenza vaccines and develop effective vaccination delivery systems. For instance, in October 2021, The Centers for Disease Control and Prevention (CDC) and the National Foundation for Infectious Diseases (NFID), along with other public health and medical organizations, jointly announced the opening of the 2020-2021 flu vaccination season, highlighting the importance of vaccination and recommending that everyone six months and older get vaccinated against flu once a year.

Figure 2. Global Microneedle Flu Vaccine Market Share (%), by Region, 2025

To learn more about this report, Request sample copy

Global Microneedle Flu Vaccine Market- Regional Analysis

Among region, North America is expected to dominate the market over the forecast period. This is attributed to the increasing adoption of organic growth strategies such as expansion by key players in the region to expand their product portfolio which is expected to drive the market growth over the forecast period. For instance, in October 2021, Vaxess Technologies Inc., engaged in developing biomedical innovations with a focus on improving access to vaccines, announced the grand opening of a Good Manufacturing Practice (GMP) manufacturing facility, a GMP Facility is a production facility or a clinical trial materials pilot plant for the manufacture of pharmaceutical products. Vaxess Technologies Inc. is focused on developing a pipeline of MIMIX therapies.

The Europe region is expected to be the second largest region over the forecast period, owing to increasing research and development activities by key players in the region to expand product portfolio, which is expected to drive the market growth over the forecast period. For instance, in October 2021, LTS Lohmann Therapie-Systeme AG, a developer and manufacturer of transdermal systems and oral thin films, announced that it has expanded the research and development area for microneedles.

Global Microneedle Flu Vaccine Market– Impact of Coronavirus (COVID-19) Pandemic

Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). According to the World Health Organization (WHO), 40 million people were affected globally till October 10, 2022.

However, the COVID-19 pandemic had a positive impact on the global microneedle flu vaccine market due to the increasing development of microneedle patches by key players in the market for the treatment of COVID-19. For instance, in April 2020, Carnegie Mellon University, a global research university, developed microneedle patches to fight COVID-19.

Global Microneedle Flu Vaccine Market Segmentation:

The global microneedle flu vaccine market report is segmented into product type, vaccine type, flu type, and region

Based on Product Type, the market is segmented into solid microneedles, hollow microneedles, coated microneedles, and dissolving microneedles. Out of which, the dissolving microneedles segment is expected to dominate the global microneedle flu vaccine market during the forecast period and this is attributed to an increase in the product launches by key players in the market.

Based on Vaccine Type, the market is segmented into trivalent flu vaccine, and quadrivalent flu vaccine. Out of which, the trivalent flu vaccine segment is expected to dominate the market over the forecast period and this is due to an increase in the use of trivalent flu vaccines for the treatment of influenza flu.

Based on Flu Type, the microneedle flu vaccine market is segmented into influenza A (H1N1, H3N1), and influenza B. Influenza A segment is expected to dominate in the market over the forecast period and this is attributed to the increase in the usage of microneedle flu vaccine to treat influenza.

Based on Region, the microneedle flu vaccine market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. Of which, North America segment is expected to dominate the market over the forecast period and this is attributed to the increasing inorganic growth strategies such as collaborations by key players in the region

Among all segmentation, product type segment has the highest potential due to the increasing adoption of research and development activities. For instance, in April 2021, a report published by National Center for Biotechnology Information (NCBI), stated that according to research, microneedles are a new generation of vaccine delivery systems.

Global Microneedle Flu Vaccine Market Cross Sectional Analysis:

In flu type segment, influenza A segment held a dominant position in North America region due to the increasing prevalence of influenza in the North America region which will expand the use of microneedle flu vaccines for treatment. For instance, on January 12, 2023, an article published by World Health Organization (WHO), stated that research estimates that 99% of deaths in children under 5 years of age with influenza-related lower respiratory tract infections are found in developing countries.

Global Microneedle Flu Vaccine Market: Key Developments

• On December 14, 2022, Vaxess Technologies, Inc., a life sciences company developing a shelf-stable vaccine patch with potential for self-application, announced positive interim results from a first-in-man trial of VX-103, a monovalent seasonal influenza vaccine patch
• On June 17, 2020, MICRODERMICS INC, a medical device company commercializing a novel microneedle delivery and biosensing platform, announced strategic merger & acquisition or technology out-licensing opportunities with pharma, cosmetic, and biotech companies for its microneedle platforms
• On August 6, 2020, EVERSANA, the leading provider of global commercial services to the life sciences industry, announced the acquisition of Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, to commercialize and distribute Qtrypta, a transdermal microneedle product
• On November 18, 2020, Sanofi, a multinational pharmaceutical and healthcare company announced that the European Commission has granted marketing authorization for Supemtek, a quadrivalent (four-strain) recombinant influenza vaccine, for the prevention of influenza in adults aged 18 years and older
• The increasing clinical trials, merger and acquisitions, product approvals, etc. is expected to generate new opportunities for the global microneedle flu vaccine market.

Global Microneedle Flu Vaccine Market: Restraint

The disadvantages of the microneedle flu vaccine

The major factors that can hamper the growth of the global microneedle flu vaccine market over the forecast period include disadvantages like it is time-consuming, it may result in scarring of the skin, etc. For instance, in December 2022, The American Society for Microbiology, an open-access journal, published an article stating that the amount of time it takes to dissolve a microneedle may range from minutes to several hours, which is a major disadvantage of using microneedles.

Therefore, overcoming the disadvantages associated with the use of microneedle flu vaccines may help in increasing the wider application of microneedle flu vaccines and can tackle these restraints.

Global Microneedle Flu Vaccine Market: Key Players

Major players operating in the global microneedle flu vaccine market  include Sanofi, GC Pharma, Harro Höfliger, CosMED Pharmaceutical Co.Ltd., Micron Biomedical, Inc., LTS Lohmann Therapie-Systeme AG, Micralyne, Inc., Sorrento Therapeutics, Inc., TSRL, Inc., QUADMEDICINE, Raphas Co., Ltd., Cutanos GmbH, 3M, NanoPass, Corium, Inc., BD, FluGen, Inc., MICRODERMICS INC

Definition: A microneedle flu vaccine makes use of different types of microneedles for the delivery of drugs and vaccines and is mainly used in the treatment of influenza